Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS109
- Development stage
- Unknown
- Lead developer
- DS Biopharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DS109 is a topical anti-inflammatory cream being developed by DS Biopharma for the treatment of inflammatory skin disorders, including acne. The drug has been evaluated in a Phase I first-in-man dose-escalation study to assess the safety and local tolerability of 1% and 5% cream formulations when applied topically to healthy volunteers. DS109 is designed as a localized anti-inflammatory compound specifically for dermatological conditions, distinguishing it from other compounds in the developer's pipeline that target fibrotic and pulmonary diseases.
Beyond the preview
Go deeper on DS109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS109.